Patents by Inventor Kiyean Nam
Kiyean Nam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11945822Abstract: The present invention relates to pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing at least one of the pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof.Type: GrantFiled: April 11, 2019Date of Patent: April 2, 2024Assignees: QURIENT CO., LTD., LEAD DISCOVERY CENTER GMBHInventors: Kiyean Nam, Jaeseung Kim, Yeejin Jeon, Donghoon Yu, Mooyoung Seo, Dongsik Park, Jan Eickhoff, Gunther Zischinsky
-
Patent number: 11858937Abstract: The present invention relates to pyrazolo [1,5-a][1,3,5]triazine and pyrazolo [1,5-a]pyrimidine derivatives having Formula I: and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing at least one of the pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof.Type: GrantFiled: April 11, 2019Date of Patent: January 2, 2024Assignees: QURIENT CO., LTD., LEAD DISCOVERY CENTER GMBHInventors: Kiyean Nam, Jaeseung Kim, Yeejin Jeon, Donghoon Yu, Mooyoung Seo, Dongsik Park, Jan Eickhoff, Gunther Zischinsky, Uwe Koch
-
Publication number: 20230141783Abstract: The present invention relates to different forms of the compound 6-chloro-2-ethyl-N-(4-(4-(4-(trifluoromethoxy)phenyl)piperidine-l-yl)benzyl)imidazo[l,2-a]pyridine-3-carboxamide and to methods of making such forms/compounds. The present invention furthermore relates to mono-acid addition salts thereof, to methods of making such mono-acid addition salts and to pharmaceutical compositions comprising any of the aforementioned compounds. Furthermore, the present invention relates to uses of any of these compounds.Type: ApplicationFiled: July 30, 2019Publication date: May 11, 2023Inventors: KIYEAN NAM, JAESEUNG KIM, CHUNWON JUNG, SAEYEON LEE
-
Publication number: 20230055208Abstract: The present invention relates to new pharmaceutical dosage forms of 6-chloro-2-ethyl-N-(4-(4-(4-(trifluoromethoxy)phenyl)piperidine-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide, in particular of its ditosylate form.Type: ApplicationFiled: December 17, 2020Publication date: February 23, 2023Inventors: KIYEAN NAM, JAESEUNG KIM, CHUNWON JUNG, SAEYEON LEE
-
Publication number: 20220387300Abstract: The present invention relates to a topical anti-inflammatory pharmaceutical composition comprising Zileuton. Furthermore, the present invention relates to uses of such composition. Moreover, the present invention relates to methods of preparing a topical anti-inflammatory pharmaceutical composition comprising Zileuton.Type: ApplicationFiled: December 30, 2019Publication date: December 8, 2022Inventors: Kiyean NAM, Jaeseung KIM, Chunwon JUNG, Jiyoong CHUN, Borami JEON
-
Patent number: 11447486Abstract: The present invention relates to benzimidazole derivatives having the general formula I, wherein n is 0 or 1; X1 and X2 are independently, at each occurrence, CR5 or N; Y is C1-C6 alkylene, wherein alkylene is optionally substituted with one to two C1-C3 alkyl groups; R1 is selected from the group consisting of hydrogen, halogen, C1-C6 alkoxy, —NH2, —NHR6, —NR7R8 and —NH—(R9)n—R10, n being 0 or 1; R2 is selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, —NH2, —NHR6, —NR7R8 and —NH—(R9)n—R10; R3 is selected from the group consisting of hydrogen, hydroxyl, OR11, —NR7R8, C1-C6 alkoxy, C1-C6 alkyl, C3-C10 cycloalkyl, C1-C3 haloalkyl, —C(O)NHR11, aryl, heteroaryl and heterocyclyl, wherein each of said cycloalkyl, aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four Ra groups; and R4 is selected from the group consisting of —NH2, —N(R12)(V)pR13, —NH(V)p—OR14, —NHC(O)R15, and groups of formula 1a shown below, and their use in the treatment of diseases, inType: GrantFiled: July 31, 2015Date of Patent: September 20, 2022Assignees: INSTITUT PASTEUR KOREA, QURIENT CO., LTD.Inventors: Jaeseung Kim, Seohyun Ahn, Yeejin Jeon, Dongsik Park, Young-In Yang, Doohyung Lee, Saeyeon Lee, Jiye Ahn, Jeongjun Kim, Kiyean Nam, Sunhee Kang, Minjung Seo, Mooyoung Seo, Jeongjea Seo, Sung-Jun Han, Jung Hwan Kim, Sangchul Lee, Gahee Choi, Yunmi Lee
-
Publication number: 20220098208Abstract: The present invention relates to pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing at least one of the pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: December 13, 2021Publication date: March 31, 2022Inventors: KIYEAN NAM, JAESEUNG KIM, YEEJIN JEON, DONGHOON YU, MOOYOUNG SEO, DONGSIK PARK, JAN EICKHOFF, GUNTHER ZISCHINSKY, UWE KOCH
-
Publication number: 20210163448Abstract: The present invention relates to quinoline derivatives which are inhibitors for Axl/Mer RTK (receptor tyrosine kinase) and CSF1R (colony stimulating factor 1 receptor). These compounds are suitable for the treatment of disorders associated with, accompanied by, caused by or induced by Axl/Mer RTK and CSF1R, in particular a hyperfunction thereof. The compounds are suitable for the treatment of hyperproliferative disorders, such as cancer, particularly immune-suppressive cancer (such as those cancers with an immunosuppression of innate immunity in a tumor microenvironment (TME), refractory cancer and cancer metastases. They are also useful in the treatment of inflammatory diseases and/or neurodegenerative diseases.Type: ApplicationFiled: May 31, 2019Publication date: June 3, 2021Inventors: KIYEAN NAM, JAESEUNG KIM, DONGSIK PARK, YEEJIN JEON, YEONG-IN YANG, HWAN KYU KANG
-
Publication number: 20210147427Abstract: The present invention relates to pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing at least one of the pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: April 11, 2019Publication date: May 20, 2021Inventors: KIYEAN NAM, JAESEUNG KIM, YEEJIN JEON, DONGHOON YU, MOOYOUNG SEO, DONGSIK PARK, JAN EICKHOFF, GUNTHER ZISCHINSKY
-
Publication number: 20210139483Abstract: The present invention relates to pyrazolo [1,5-a] [1,3,5]triazine and pyrazolo[1,5-a] pyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing at least one of the pyrazolo [1,5-a][1,3,5]triazine and pyrazolo [1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: April 11, 2019Publication date: May 13, 2021Inventors: KIYEAN NAM, JAESEUNG KIM, YEEJIN JEON, DONGHOON YU, MOOYOUNG SEO, DONGSIK PARK, JAN EICKHOFF, GUNTHER ZISCHINSKY, UWE KOCH
-
Patent number: 10934274Abstract: The present invention relates to novel compounds which are inhibitors of TAM (Axl, Mer and Tyro 3) and/or Met family receptor tyrosine kinases (RTKs). These compounds are suitable for the treatment of disorders associated with, accompanied by, caused by or induced by a receptor of the TAM family, in particular a hyperfunction thereof. The compounds are suitable for the treatment of hyperproliferative disorders, such as cancer, particularly immune-suppressive cancer, refractory cancer and cancer metastases.Type: GrantFiled: April 14, 2016Date of Patent: March 2, 2021Assignees: QURIENT CO., LTD., LEAD DISCOVERY CENTER GMBHInventors: Kiyean Nam, Jaeseung Kim, Seohyun Ahn, Yeejin Jeon, Doohyung Lee, Dongsik Park, Young-In Yang, SaeYeon Lee, Jeongjun Kim, Jiye Ahn, Hana Kim, Chun-won Jung, Carsten Schultz-Fademrecht
-
Publication number: 20180093968Abstract: The present invention relates to novel compounds which are inhibitors of TAM (Axl, Mer and Tyro 3) and/or Met family receptor tyrosine kinases (RTKs). These compounds are suitable for the treatment of disorders associated with, accompanied by, caused by or induced by a receptor of the TAM family, in particular a hyperfunction thereof. The compounds are suitable for the treatment of hyperproliferative disorders, such as cancer, particularly immune-suppressive cancer, refractory cancer and cancer metastases.Type: ApplicationFiled: April 14, 2016Publication date: April 5, 2018Inventors: Kiyean NAM, Jaeseung KIM, Seohyun AHN, Yeejin JEON, Doohyung LEE, Dongsik PARK, Young-In YANG, SaeYeon LEE, Jeongjun KIM, Jiye AHN, Hana KIM, Chun-won JUNG, Carsten SCHULTZ-FADEMRECHT
-
Publication number: 20170166563Abstract: The present invention relates to benzimidazole derivatives having the general formula I, wherein n is 0 or 1; X1 and X2 are independently, at each occurrence, CR5 or N; Y is C1-C6 alkylene, wherein alkylene is optionally substituted with one to two C1-C3 alkyl groups; R1 is selected from the group consisting of hydrogen, halogen, C1-C6 alkoxy, —NH2, —NHR6, —NR7R8 and —NH—(R9)n—R10, n being 0 or 1; R2 is selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, —NH2, —NHR6, —NR7R8 and —NH—(R9)n—R10; R3 is selected from the group consisting of hydrogen, hydroxyl, OR11, —NR7R8, C1-C6 alkoxy, C1-C6 alkyl, C3- C10 cycloalkyl, C1-C3 haloalkyl, —C(O)NHR11, aryl, heteroaryl and heterocyclyl, wherein each of said cycloalkyl, aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four Ra groups; and R4 is selected from the group consisting of —NH2, —N(R12)(V)pR13, —NH(V)p—OR14, —NHC(O)R15, and groups of formula 1a shown below, and their use in the treatment of diseases, inType: ApplicationFiled: July 31, 2015Publication date: June 15, 2017Inventors: JAESEUNG KIM, SEOHYUN AHN, YEEJIN JEON, DONGSIK PARK, YOUNG-IN YANG, DOOHYUNG LEE, SAEYEON LEE, JIYE AHN, JEONGJUN KIM, KIYEAN NAM, SUNHEE KANG, MINJUNG SEO, MOOYOUNG SEO, JEONGJEA SEO, SUNG-JUN HAN, JUNG HWAN KIM, SANGCHUL LEE, GAHEE CHOI, YUNMI LEE
-
Publication number: 20160185774Abstract: The present invention relates to small molecule compounds and their use in the treatment of bacterial infections, in particular Tuberculosis.Type: ApplicationFiled: August 1, 2014Publication date: June 30, 2016Inventors: Jaeseung KIM, Sunhee KANG, Min Jung SEO, Mooyoung SEO, Jeongjea SEO, Sumi LEE, Juhee KANG, Dongsik PARK, Ryang Yeo KIM, Kevin PETHE, Kiyean NAM, Jeongjun KIM, Soohyun OH, Saeyeon LEE, Jiye AHN
-
Patent number: 9029389Abstract: The present invention refers to: a compound having the general formula (I), wherein n is 0, 1, 2 or; m is 0, 1, 2 or 3; o is 0, 1, 2 or 3; W, X, Y and Z are independently selected from CH, N or N-oxide; A is NR4, C?O, C?S, OP(O)(O), P?O, CH2, or a heteroarly selected from the group consisting of (a), (b), (c), (d), (e), (f), (g); V is C?O, O, S, CH2, or NR5; as well as its use in treating inflammatory diseases such as asthma, COPD, inflammation post infection, arthritis, atherosclerosis, pain and dermatitis.Type: GrantFiled: April 20, 2012Date of Patent: May 12, 2015Assignees: Institut Pasteur Korea, Qurient Co. LtdInventors: Zaesung No, Jaeseung Kim, Sung-Jun Han, Jung Hwan Kim, Young Sam Park, Sangchul Lee, Kiyean Nam, Jeongjun Kim, Jinhwa Lee, Sunhee Kang, Min Jung Seo, Saeyeon Lee, Gahee Choi
-
Publication number: 20140155387Abstract: The present invention refers to: a compound having the general formula (I), wherein n is 0, 1, 2 or; m is 0, 1, 2 or 3; o is 0, 1, 2 or 3; W, X, Y and Z are independently selected from CH, N or N-oxide; A is NR4, C?O, C?S, OP(O)(O), P?O, CH2, or a heteroarly selected from the group consisting of (a), (b), (c), (d), (e), (f), (g); V is C?O, O, S, CH2, or NR5; as well as its use in treating inflammatory diseases such as asthma, COPD, inflammation post infection, arthritis, atherosclerosis, pain and dermatitis.Type: ApplicationFiled: April 20, 2012Publication date: June 5, 2014Applicants: QURIENT, CO. LTD., INSTITUT PASTEUR KOREAInventors: Zaesung No, Jaeseung Kim, Sung-Jun Han, Jung Hwan Kim, Young Sam Park, Sangchul Lee, Kiyean Nam, Jeongjun Kim, Jinhwa Lee, Sunhee Kang, Min Jung Seo, Saeyeon Lee, Gahee Choi